Khronicheskaya migren': novye perspektivy diagnostiki i lecheniya
- Авторлар: Azimova Y.E1
-
Мекемелер:
- Шығарылым: № 13 (2013)
- Беттер: 75-80
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/282294
- ID: 282294
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
Chronic migraine is a severe maladaptive disease, the pathogenesis of which is actively being studied, and the criteria and approaches to the treatment are continuously developed. One of the most studied drugs in the treatment of chronic migraine is a botulinum toxin type A (Botox®). PREEMT is the large-scale study of patients with chronic migraine, which consists of two parts: a 24-week double-blind, placebo-controlled phase of the random distribution, and a 32-week open-label phase. The study showed a significant reduction in the number of days with headache in the Botox® group compared with the placebo group, and the superiority of Botox® for a number of secondary efficacy parameters, including the degree of maladjustment.
Негізгі сөздер
Толық мәтін
Әдебиет тізімі
- Международная классификация головных болей 2-е издание (полная русскоязычная версия). 2006. 380 с.
- Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;4(Suppl. 1):S9-15.
- Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
- Aurora SK, Winner P, Freeman MC, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51:1358-73.
- Azimova Y, Sergeev A, Skorobogatykh K. BDNF gene polymorphysm RS2049046 in episodic and chronic migraine. J Headache and Pain 2013;(Suppl 1):16.
- Bigal ME, Ashina S, Burstein R, et al. Prevalence and characteristics of allodynia in headache sufferers: a population study. Neurology 2008;70:1525-33.
- Coppola G, Schoenen J. Cortical excitability in chronic migraine. Curr Pain Headache Rep 2012;16:93-100.
- Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-14.
- Dodick DW, Turkel CC, DeGryse RE, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the doubleblind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36.
- Dodick DW. Review of comorbidities and risk factors for the development of migraine complications (infarct and chronic migraine). Cephalalgia 2009;29(Suppl. 3):7-14.
- Durham PL, Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache 2011;51:1573-77.
- Frampton JE. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine. Drugs 2012;72:825-45.
- Kagan R, Kainz V, Burstein R, et al. Hypothalamic and basal ganglia projections to the posterior thalamus: Possible role in modulation of migraine headache and photophobia. Neuroscience 2013;248:359-68.
- Lakhan SE, Avramut M, Tepper SJ. Structural and functional neuroimaging in migraine: insights from 3 decades of research. Headache 2013;53:46-66.
- Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache 2009;49:498-508.
- Mustafa G, Anderson EM, Bokrand-Donatelli Y, et al. Anti-nociceptive effect of a conjugate of substance P and light chain of botulinum neurotoxin type A. Pain 2013:S0304-3959.
- Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996;47:871-75.
- Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.
- The International Classification of Headache Disorders, 3rd edition (beta version). Headache Classification Committee of the International Headache Society (IHS). Cephalalgia 2013;33:629-808.
- Valfr W, Rainero I, Bergui M, et al. Voxel-based morphometry reveals gray matter abnormalities in migraine. Headache 2008;48:109-17.
- Vos T, Flaxman A, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2163-219.
- Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. PLoS One 2013; 8:е54074.
Қосымша файлдар
